Otsuka’s ADHD Drug Symtrio Wins FDA Approval, With Annual Sales Target of 915 Billion Won

Otsuka Pharmaceutical’s attention-deficit/hyperactivity disorder (ADHD) treatment Symtrio has received approval from the US Food and Drug Administration (FDA) for patients aged 6 and older. The drug, the first NDSRI in its class, demonstrated significant improvement in ADHD symptoms compared with placebo in four phase 3 clinical trials. Otsuka is targeting annual sales of up to 100 billion yen (approximately 915 billion won); the drug is part of Neurovance’s pipeline, which Otsuka acquired for $100 million in 2017.